Evidence map›Paper›PMID 38099588›Full record

ArticleClinical and translational gastroenterology2024

Serum Exosome-Derived microRNA-193a-5p and miR-381-3p Regulate Adenosine 5'-Monophosphate-Activated Protein Kinase/Transforming Growth Factor Beta/Smad2/3 Signaling Pathway and Promote Fibrogenesis.

Sihao Wang, Yan Chen, Guanglin Lei, Xuemei Ma, Linjing An, Han Wang, Zheng Song, Li Lin, Quanwei He, Ran Xu and 3 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Sihao WangDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Yan ChenDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Guanglin LeiDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Xuemei MaDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Linjing AnDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Han WangDepartment of Blood Transfusion, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Zheng SongPeking University 302 Clinical Medical School, Beijing, China.
Li LinDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Quanwei HeDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Ran XuDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Xiaoyan ZhanDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Zhaofang BaiDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Yongping YangDepartment of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Chinese PLA General Hospital · CNPeking University · CN

Funding

Ministry of Science and Technology of the People's Republic of China 2013ZX10005002,2018ZX10725506
6 · The paper itself

Abstract

introductionLiver fibrosis results from chronic liver injury and inflammation, often leading to cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. Progress has been made in understanding the molecular mechanisms underlying hepatic fibrosis; however, translating this knowledge into effective therapies for disease regression remains a challenge, with considerably few interventions having entered clinical validation. The roles of exosomes during fibrogenesis and their potential as a therapeutic approach for reversing fibrosis have gained significant interest. This study aimed to investigate the association between microRNAs (miRNAs) derived from serum exosomes and liver fibrosis and to evaluate the effect of serum exosomes on fibrogenesis and fibrosis reversal, while identifying the underlying mechanism.

methodsUsing serum samples collected from healthy adults and paired histologic patients with advanced fibrosis or cirrhosis, we extracted human serum exosomes by ultrahigh-speed centrifugation. Transcriptomic analysis was conducted to identify dysregulated exosome-derived miRNAs. Liver fibrosis-related molecules were determined by qRT-PCR, Western blot, Masson staining, and immunohistochemical staining. In addition, we analyzed the importance of serum exosome-derived miRNA expression levels in 42 patients with advanced fibrosis or cirrhosis.

resultsExosome-derived miR-193a-5p and miR-381-3p were associated with fibrogenesis, as determined by transcriptomic screening. Compared with healthy control group, the high expression of serum exosome-derived miR-193a-5p and miR-381-3 in chronic hepatitis B (n = 42) was closely associated with advanced liver fibrosis and cirrhosis. In vitro , exosome-derived miRNA-193a-5p and miR-381-3p upregulated the expression of α-smooth muscle actin, collagen 1a1, and tissue inhibitors of metalloproteinase 1 in the human hepatic stellate cell line at both mRNA and protein levels. DISCUSSION: Serum exosome-derived miR-193a-5p and miR-381-3p regulated the adenosine 5'-monophosphate-activated protein kinase/transforming growth factor beta/Smad2/3 signaling pathway and promoted fibrogenesis.

Indexed as

ExosomesMicroRNAsAdenosineAdultHumansLiver CirrhosisProtein KinasesSignal TransductionTransforming Growth Factor betaAdenosineMicroRNAsMIRN381 microRNA, humanProtein KinasesTransforming Growth Factor beta

Identifiers

PMID38099588
PMCPMC10887447
OpenAlexW4389784626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.